These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33634954)

  • 41. Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.
    Mazza R; Maher J
    Arch Immunol Ther Exp (Warsz); 2021 Dec; 70(1):2. PubMed ID: 34897554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
    Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
    Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
    Zhu H; Kaufman DS
    Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
    Sabbah M; Jondreville L; Lacan C; Norol F; Vieillard V; Roos-Weil D; Nguyen S
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.
    Marofi F; Rahman HS; Thangavelu L; Dorofeev A; Bayas-Morejón F; Shirafkan N; Shomali N; Chartrand MS; Jarahian M; Vahedi G; Mohammed RN; Shahrokh S; Akbari M; Khiavi FM
    Stem Cell Res Ther; 2021 Mar; 12(1):200. PubMed ID: 33752707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
    Schmidt P; Raftery MJ; Pecher G
    Front Immunol; 2020; 11():611163. PubMed ID: 33488617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies.
    Lu H; Zhao X; Li Z; Hu Y; Wang H
    Front Oncol; 2021; 11():720501. PubMed ID: 34422667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
    Netsrithong R; Wattanapanitch M
    Front Immunol; 2021; 12():759558. PubMed ID: 34650571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
    Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
    Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
    Front Immunol; 2020; 11():581468. PubMed ID: 33193388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CAR-NK cells: a promising cellular immunotherapy in lymphoma.
    Khanmohammadi S; Rezaei N
    Expert Opin Biol Ther; 2023 Jan; 23(1):37-47. PubMed ID: 36453808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.
    Luevano M; Domogala A; Blundell M; Jackson N; Pedroza-Pacheco I; Derniame S; Escobedo-Cousin M; Querol S; Thrasher A; Madrigal A; Saudemont A
    PLoS One; 2014; 9(1):e87086. PubMed ID: 24489840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.
    Oelsner S; Waldmann A; Billmeier A; Röder J; Lindner A; Ullrich E; Marschalek R; Dotti G; Jung G; Große-Hovest L; Oberoi P; Bader P; Wels WS
    Int J Cancer; 2019 Oct; 145(7):1935-1945. PubMed ID: 30860598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.